0 results available. Select is focused ,type to refine list, press Down to open the menu,
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company’s product pipeline includes Plozasiran, which has completed Phase 3 clini...
The following section summarizes insights on Arrowhead Pharmaceuticals Inc's Net Income to Stockholders Margin:
To view the full list of supported financial metrics please see Complete Metrics Listing.
Metrics similar to Net Income to Stockholders Margin in the efficiency category include:
A ratio that measures the amount of profit that stockholders earn on each dollar of revenue earned by the firm.
The net income to stockholders margin measures a company’s net income to stockholders as a percentage of the revenue. The formula to calculate net income to stockholders margin and an example calculation for Arrowhead Pharmaceuticals’s trailing twelve months is outlined below:
Net Income to Stockholders Margin = Net Income to Stockholders / Total Revenue
−25,588.6% = -639.7 M / 2.5 M
The tables below summarizes Arrowhead Pharmaceuticals’s performance over the last five years:
| Fiscal Year | Net Income to Stockholders | Revenue | Margin |
|---|---|---|---|
| 2020-09-30 | -84.553 M | 87.992 M | −96.1% |
| 2021-09-30 | -140.8 M | 138.3 M | −101.9% |
| 2022-09-30 | -176.1 M | 243.2 M | −72.4% |
| 2023-09-30 | -205.3 M | 240.7 M | −85.3% |
| 2024-09-30 | -599.5 M | 3.551 M | −16,882.4% |
The tables below summarizes Arrowhead Pharmaceuticals’s performance over the last four quarters:
| Quarter Ending | Net Income to Stockholders | Revenue | Margin |
|---|---|---|---|
| 2024-03-31 | -125.3 M | zero | NA |
| 2024-06-30 | -170.8 M | zero | NA |
| 2024-09-30 | -170.5 M | zero | NA |
| 2024-12-31 | -173.1 M | 2.5 M | −6,923.4% |
You can read more about Net Income to Stockholders here.
The chart above depicts the distribution of net income to stockholders margin for companies operating in the Healthcare sector in the Developed economic region. Over 2,010 companies were considered in this analysis, and 1,931 had meaningful values. The average net income to stockholders margin of companies in the sector is -1,135.0% with a standard deviation of 4,278.9%.
Arrowhead Pharmaceuticals Inc's Net Income to Stockholders Margin of -25,588.6% ranks in the 2.5% percentile for the sector. The following table provides additional summary stats:
| Economic Risk Region | Developed |
| Total Constituents | 2,011 |
| Included Constituents | 1,931 |
| Min | -45,635.8% |
| Max | 105.1% |
| Median | -25.9% |
| Mean | -1,135.0% |
| Standard Deviation | 4,278.9% |
You can find companies with similar net income to stockholders margin using this stock screener.